Tirzepatide: clinical trials recruiting now
55
Recruiting trials
15
Conditions studied
44
US states with sites
40
Countries
FDA drug label
- FDA-approved
- Yes. Tirzepatide appears in the FDA drug-label database. Marketed as MOUNJARO.
- Drug class
- Glucose-dependent Insulinotropic Polypeptide Receptor Agonist; GLP-1 Receptor Agonist (FDA established pharmacologic class)
- Mechanism of action
- G-Protein-linked Receptor Interactions; Glucagon-like Peptide-1 (GLP-1) Agonists (as stated on the FDA label)
- Boxed warning
- The FDA label for Tirzepatide carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )
Phase breakdown
Early Phase 1 4
Phase 1 4
Phase 2 21
Phase 3 7
Phase 4 18
Not applicable 5
Conditions being studied
Recruiting trials involving Tirzepatide
- 2024 Tirzepatide-Bariatric Surgery
- A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- A Study of BGM0504 in Participants With Obesity
- A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer
- A Study to Evaluate ALN-2232 in Participants With Obesity
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
- Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
- Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
- Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
- Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
- Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
- Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
- Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- GLP-1R Actions on Muscle and the Skeleton
- Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
- Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
- Incretin Therapies in Obesity-related HFpEF
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
- Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
- Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
- Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
- Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
- Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
- Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
- Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
- TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
- The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
- Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
- Tirzepatide Use in People With Obesity and Type 1 Diabetes
- Tirzepatide Weight Loss for MRD+ Early Breast Cancer
- Tirzepatide and Muscle Outcomes in Obesity
- Tirzepatide for Alcohol Use Disorder
- Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- Tirzepatide in Idiopathic Intracranial Hypertension Trial
- Tirzepatide in Obesity-Driven Endometrial Cancer
- Tirzepatide in PWS, HO and GNSO
- Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
- Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Common questions
Is Tirzepatide FDA-approved?
Yes, marketed as MOUNJARO. Its FDA label carries a boxed warning.
How many recruiting trials involve Tirzepatide?
55 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.